Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Zaiss

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Onkologie|August 8, 2012
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxibNorbert Marschner, Matthias Zaiss
European Journal of Haematology|July 22, 2006
Differentiation of hematopoietic progenitor cells towards the myeloid and B-lymphoid lineage by hepatocyte growth factor (HGF) and thrombopoietin (TPO) together with early acting cytokinesJochen Grassinger, Gunnar Mueller, Matthias Zaiss, et al.
Experimental Hematology|September 10, 2003
CD84 expression on human hematopoietic progenitor cellsMatthias Zaiss, Christian Hirtreiter, Michael Rehli, et al.
Oncology Research and Treatment|September 8, 2021
Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANOMatthias Zaiss, Jens Uhlig, Mark-Oliver Zahn, et al.
Annals of Hematology|February 29, 2024
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe studyIngo Schwaner, Thomas Kuhn, Christoph Losem, et al.
Journal of Cancer Research and Clinical Oncology|October 21, 2025
Response to PD-1 inhibition in MMRd/MSS pancreatic ductal adenocarcinoma: the relevance of parallel testingHeike L Pahl, Silke Lassmann, Anne M Schultheis, et al.
Breast Cancer Research and Treatment|September 12, 2022
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)Marc Thill, Pauline Wimberger, Andrea Grafe, et al.
Stem Cells (Dayton, Ohio)|July 28, 2004
Expression and function of homing-essential molecules and enhanced in vivo homing ability of human peripheral blood-derived hematopoietic progenitor cells after stimulation with stem cell factorChristina Hart, Diana Drewel, Gunnar Mueller, et al.
Current Medical Research and Opinion|December 18, 2018
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIRThomas Fietz, Andreas Lück, Holger Schulz, et al.
Oncology Research and Treatment|December 23, 2014
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance studyVolkmar Müller, Stefan Fuxius, Claus-Christoph Steffens, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Onkologie|August 8, 2012
Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxibNorbert Marschner, Matthias Zaiss
European Journal of Haematology|July 22, 2006
Differentiation of hematopoietic progenitor cells towards the myeloid and B-lymphoid lineage by hepatocyte growth factor (HGF) and thrombopoietin (TPO) together with early acting cytokinesJochen Grassinger, Gunnar Mueller, Matthias Zaiss, et al.
Experimental Hematology|September 10, 2003
CD84 expression on human hematopoietic progenitor cellsMatthias Zaiss, Christian Hirtreiter, Michael Rehli, et al.
Oncology Research and Treatment|September 8, 2021
Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANOMatthias Zaiss, Jens Uhlig, Mark-Oliver Zahn, et al.
Annals of Hematology|February 29, 2024
Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe studyIngo Schwaner, Thomas Kuhn, Christoph Losem, et al.
Journal of Cancer Research and Clinical Oncology|October 21, 2025
Response to PD-1 inhibition in MMRd/MSS pancreatic ductal adenocarcinoma: the relevance of parallel testingHeike L Pahl, Silke Lassmann, Anne M Schultheis, et al.
Breast Cancer Research and Treatment|September 12, 2022
Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)Marc Thill, Pauline Wimberger, Andrea Grafe, et al.
Stem Cells (Dayton, Ohio)|July 28, 2004
Expression and function of homing-essential molecules and enhanced in vivo homing ability of human peripheral blood-derived hematopoietic progenitor cells after stimulation with stem cell factorChristina Hart, Diana Drewel, Gunnar Mueller, et al.
Current Medical Research and Opinion|December 18, 2018
Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIRThomas Fietz, Andreas Lück, Holger Schulz, et al.
Oncology Research and Treatment|December 23, 2014
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance studyVolkmar Müller, Stefan Fuxius, Claus-Christoph Steffens, et al.
Pageof 3